

Siemens Healthcare Diagnostics GmbH, SHS EMEA CEET QT, Siemensstrasse 90,
1210 Vienna

Name M.A. Roland Ertl
 Department SHS EMEA CEET QT
 Mobile +43 (664) 8855 6167
 E-mail roland.re.ertl@siemens-healthineers.com
 Date August 29th, 2024
 Document Ref# ACHC24-05.A.OUS

Urgent Field Safety Notice:

**Atellica CH Analyzer
 Atellica CI Analyzer**

Atellica CH Microalbumin_2 (μALB_2) Assay High-Dose Hook Effect

To whom it may concern,

Siemens Healthineers has confirmed, through an investigation, the Atellica[®] CH Microalbumin_2 (μALB_2) lots listed in the table below are not meeting the High-Dose Hook Effect claim as stated in the Instructions for Use (IFU) on the Atellica[®] CH and Atellica[®] CI Analyzers.

The Atellica CH μALB_2 Measuring Interval is 0.3–38.0 mg/dL (3–380 mg/L). The IFU states that “High microalbumin levels can cause a paradoxical decrease in signal as a result of the high-dose hook effect. In the Atellica CH μALB_2 assay, microalbumin levels as high as 20,000 mg/dL (200,000 mg/L) will read > 38.0 mg/dL (> 380 mg/L).”

For the lots in the table below (Products Section), the high-dose hook effect claim begins to fail at concentrations greater than 9,500 mg/dL (95,000 mg/L).

| Assay | Test Code | Siemens Material Number/ Unique Device Identification | Lot Number | Expiration Date |
|-------------------------------|-----------|--|------------|-----------------|
| Atellica CH Microalbumin_2 | μALB_2 | 11097610/ 00630414596310 | 232033 | 1-Dec-2024 |
| | | | 232128 | 1-Dec-2024 |
| | | | 232137 | 1-Dec-2024 |
| | | | 232146 | 1-Dec-2024 |
| | | | 232147 | 1-Dec-2024 |
| | | | 242149 | 1-Apr-2025 |
| | | | 242150 | 1-Apr-2025 |
| | | | 242365 | 1-Sep-2025 |

Impact to Results

Erroneously depressed microalbumin patient results may occur due to this issue. Internal testing has demonstrated there is a potential for a result of 19,063 mg/dL (190,630 mg/L) to be reported as low as 15.9 mg/dL (159 mg/L). Results of this assay should always be interpreted in conjunction with the patient's medical history, clinical presentation, and other findings.

Customer Actions

- Please review this letter with your Medical Director to determine the appropriate course of action, including for any previously generated results, if applicable.
- Customers can continue to use the impacted μ ALB_2 lots in the table above (Products Section), with the understanding that patient samples with values above 9,500 mg/dL (95,000 mg/L) can result in falsely depressed results.
- Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days.
- Please retain this letter with your laboratory records and forward this letter to those who may have received this product.

Resolution

Lots 242194, 242195, and 242321 meet the IFU high-dose hook effect claim. The manufacturing control system has been updated to ensure that there is no impact to future lots.

We apologize for the inconvenience this situation may cause. If you have any questions, please contact your Siemens Healthineers Customer Care Center or your local Siemens Healthineers technical support representative.

Sincerely yours,

Siemens Healthcare Diagnostics GmbH

Signature:



*Electronically signed by: Roland Ertl
Reason: I am approving this document
Date: Aug 21, 2024 12:49 GMT+2*

Email: roland.re.ertl@siemens-healthineers.com

i.V. Roland Ertl, MA
Quality Management CEECA

Signature:



*Electronically signed by: Carina Marie
Viehboeck
Reason: I have reviewed this document
Date: Aug 21, 2024 15:34 GMT+2*

Email: carina-marie.viehboeck@siemens-healthineers.com

i.A. Dipl-Ingⁱⁿ Carina Viehböck
Product Manager CEE